IP Library Granted Patent US 10,961,578
Granted Patent B2
US 10,961,578 · App. 15/010,132 · Granted Mar 30, 2021

Methods of detecting prenatal or pregnancy-related diseases or conditions

Inventor: Amin I. Kassis (Chestnut Hill, MA)
Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
C12Q1/6883C12Q2600/106C12Q2600/118C12Q2600/136C12Q2600/158C12Q2600/16C12Q2600/178G01N33/5047G01N33/5094G01N33/56972G01N33/6842G01N33/92G01N2500/10G01N2800/368G01N2800/50G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,961,578
App. No.
15/010,132
Granted
Mar 30, 2021
Kind
B2
Abstract

This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of prenatal or pregnancy-related diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of prenatal or pregnancy-related diseases or conditions.

Claims (7)

1. An assay for detecting a marker of premature birth in a human subject, the assay comprising

a) isolating, from the blood of the human subject, a population of the subject's macrophage cells having a DNA content more than 2n (>2n macrophage cells) from macrophage cells having a DNA content of 2n (=2n cells), measuring a first nucleic acid profile of one or more markers in the isolated >2n macrophage cells, and detecting a first gene expression profile of the marker of premature birth; and

b) measuring a second nucleic acid profile of the marker of premature birth from a population of the subject's non-phagocytic cells obtained from the blood of the human subject and detecting a second gene expression profile of the marker of premature birth.

2. The assay of claim 1 , further comprising lysing the >2n macrophage cells and the non-phagocytic cells before performing the detecting.

3. The assay of claim 1 , further comprising extracting cellular contents from the >2n macrophage cells and the non-phagocytic cells before performing the detecting.

4. The assay of claim 3 , wherein the cellular contents of the >2n macrophage cells comprise viable diseased cells, dead diseased cells, apoptotic diseased cells, circulating tumor cells, infectious agents, fetal cells, trophoblasts, or fragments thereof.

5. The assay of claim 1 , wherein the >2n macrophage cells are isolated by using a cell surface target on the surface of the macrophage cells.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 4, 2022
From: HARVARD UNIVERSITY
To: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 058570/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2016
From: KASSIS, AMIN I.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 039427/0265 →
Continuity (3)
Continuation 13811682
Provisional Application 61367068 · Jul 23, 2010
Related Publication 20160145690A1 · May 26, 2016